Precision medicine for the management of NAFLD - Are we there yet?

 Metabolism, alcohol and toxicity

Room 3

Interactive Session
29 August 2020 15:30 - 17:00

NAFLD is a growing epidemics due to the increasing obesity Worldwide. The effort in finding drugs against this disease has not lead so far to an effective treatment. One of the reasons for this failure may be that NAFLD is an heterogenous disease and therefore  precision medicine may be needed for each specific NAFLD subset.  Human and molecular genetics coupled with studies on the lipidome and the epigenome have shed light into the heterogenous nature of the disease. In the lectures the speakers are encouraged to highlight:

  • How genetic determinants of NAFLD interact with the environment and is there a case for selecting patients undergoing weight loss treatment to ameliorate NAFLD based on this?
  • What have we learned from epigenetics as to defining subsets of NAFLD and what could learn more?
  • What is the key message from lipidomic studies on NAFLD heterogeneity and will this result in helpful tool for treating or diagnosing those with NAFLD?
  • Is there a case yet or will it be in the near future for Precision Medicine in NAFLD?

Presentations

Title Time

Add to Calendar

Welcome and Introduction
29 August 2020 15:30 - 15:35
Vote
29 August 2020 15:35 - 15:35
Precision medicine to stratify the risk of fatty liver disease progression
29 August 2020 15:35 - 15:50
Genetic determinants of liver disease in metabolically challenged individuals
29 August 2020 15:50 - 16:05
Epigenetic signatures increasing the risk of fatty liver disease
29 August 2020 16:05 - 16:20
Lipidomics to understand genetic vs. metabolic fatty liver disease
29 August 2020 16:20 - 16:35
Roundtable discussion and closing remarks
29 August 2020 16:35 - 17:00
Vote
29 August 2020 17:00 - 17:00